Literature DB >> 25947099

The role of anti-angiogenesis in non-small-cell lung cancer: an update.

Liza C Villaruz1, Mark A Socinski.   

Abstract

Recognition of the vascular endothelial growth factor (VEGF) pathway as a key mediator of angiogenesis has led to the clinical study of several VEGF and VEGF receptor (VEGFR) targeted therapies in non-small-cell lung cancer (NSCLC). These targeted therapies include neutralizing antibodies to VEGF (bevacizumab and aflibercept) and VEGFR-2 (ramucirumab) and tyrosine kinase inhibitors (TKIs) with selectivity for the VEGFRs. Bevacizumab and ramucirumab are associated with survival advantages in the treatment of advanced NSCLC: bevacizumab in the first-line setting in combination with carboplatin/paclitaxel and ramucirumab in combination with docetaxel in the second-line setting. The VEGFR-2 TKIs have been associated with responses and improved progression-free survival in selected NSCLC settings; however, this level of activity has thus far been insufficient to confer significant survival advantages. This review will focus on the current state of VEGF targeted therapies in NSCLC.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25947099      PMCID： PMC4836185          DOI： 10.1007/s11912-015-0448-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  78 in total

1.  Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

Authors:  Roy S Herbst; Rafat Ansari; Frederique Bustin; Patrick Flynn; Lowell Hart; Gregory A Otterson; Gordana Vlahovic; Chang-Heok Soh; Paula O'Connor; John Hainsworth
Journal:  Lancet       Date:  2011-05-28       Impact factor: 79.321

2.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.

Authors:  E Tischer; R Mitchell; T Hartman; M Silva; D Gospodarowicz; J C Fiddes; J A Abraham
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

3.  A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

Authors:  M Reck; R Kaiser; C Eschbach; M Stefanic; J Love; U Gatzemeier; P Stopfer; J von Pawel
Journal:  Ann Oncol       Date:  2011-01-06       Impact factor: 32.976

4.  A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.

Authors:  G R Blumenschein; F Kabbinavar; H Menon; T S K Mok; J Stephenson; J T Beck; K Lakshmaiah; K Reckamp; Y-J Hei; K Kracht; Y-N Sun; R Sikorski; L Schwartzberg
Journal:  Ann Oncol       Date:  2011-02-14       Impact factor: 32.976

5.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.

Authors:  B Millauer; S Wizigmann-Voos; H Schnürch; R Martinez; N P Møller; W Risau; A Ullrich
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

6.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

Authors:  K A Houck; N Ferrara; J Winer; G Cachianes; B Li; D W Leung
Journal:  Mol Endocrinol       Date:  1991-12

7.  Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.

Authors:  Giorgio V Scagliotti; Maciej Krzakowski; Aleksandra Szczesna; Janos Strausz; Anatoly Makhson; Martin Reck; Rafal F Wierzbicki; Istvan Albert; Michael Thomas; Jose Elias Abrao Miziara; Zsolt S Papai; Nina Karaseva; Sumitra Thongprasert; Elsa Dalmau Portulas; Joachim von Pawel; Ke Zhang; Paulina Selaru; Lesley Tye; Richard C Chao; Ramaswamy Govindan
Journal:  J Clin Oncol       Date:  2012-05-07       Impact factor: 44.544

8.  Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).

Authors:  Jin Soo Lee; Vera Hirsh; Keunchil Park; Shukui Qin; Cesar R Blajman; Reury-Perng Perng; Yuh-Min Chen; Laura Emerson; Peter Langmuir; Christian Manegold
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

9.  Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.

Authors:  Eng-Huat Tan; Glenwood D Goss; Ravi Salgia; Benjamin Besse; David R Gandara; Nasser H Hanna; James Chih-Hsin Yang; Raymond Thertulien; Michael Wertheim; Julien Mazieres; Thomas Hensing; Christa Lee; Neeraj Gupta; Rajendra Pradhan; Jiang Qian; Qin Qin; Frank A Scappaticci; Justin L Ricker; Dawn M Carlson; Ross A Soo
Journal:  J Thorac Oncol       Date:  2011-08       Impact factor: 15.609

Review 10.  Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.

Authors:  M Reck; F Barlesi; L Crinò; C I Henschke; D Isla; S Stiebeler; D R Spigel
Journal:  Ann Oncol       Date:  2011-11-04       Impact factor: 32.976
View more
  21 in total

Review 1.  Nintedanib in NSCLC: evidence to date and place in therapy.

Authors:  Giuseppe Bronte; Francesco Passiglia; Antonio Galvano; Nadia Barraco; Angela Listì; Marta Castiglia; Sergio Rizzo; Eugenio Fiorentino; Viviana Bazan; Antonio Russo
Journal:  Ther Adv Med Oncol       Date:  2016-02-16       Impact factor: 8.168

Review 2.  A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach.

Authors:  Andy Wai Kan Yeung; Mohamed M Abdel-Daim; Abdelrahman Ibrahim Abushouk; Kazuaki Kadonosono
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-03-02       Impact factor: 3.000

3.  Tannic Acid Exhibits Antiangiogenesis Activity in Nonsmall-Cell Lung Cancer Cells.

Authors:  Elham Hatami; Prashanth K B Nagesh; Mohammed Sikander; Anupam Dhasmana; Subhash C Chauhan; Meena Jaggi; Murali M Yallapu
Journal:  ACS Omega       Date:  2022-06-28

4.  MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer.

Authors:  Duo Li; Dong-Qiong Li; Dan Liu; Xiao-Jun Tang
Journal:  Cell Oncol (Dordr)       Date:  2016-01-07       Impact factor: 6.730

5.  Efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma: a retrospective analysis.

Authors:  Qiong Zhan; Feng Miao; Ruofan Huang; Xinli Zhou; Mengxi Ge; Xiaohua Liang
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

6.  Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study.

Authors:  Wenxia Hu; Bin Li; Nan Geng; Xin He; Hui Ge; Ping Wang; Cuimin Ding
Journal:  Int J Gen Med       Date:  2021-06-21

Review 7.  The relationship between COPD and lung cancer.

Authors:  A L Durham; I M Adcock
Journal:  Lung Cancer       Date:  2015-08-29       Impact factor: 5.705

8.  Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma.

Authors:  Natália Bertoni; Lied M S Pereira; Fábio E Severino; Regina Moura; Winston B Yoshida; Patricia P Reis
Journal:  BMC Med Genet       Date:  2016-01-15       Impact factor: 2.103

9.  Evaluation of efficacy and safety for bevacizumab in treating malignant pleural effusions caused by lung cancer through intrapleural injection.

Authors:  Sun Zongwen; Kong Song; Zhao Cong; Fu Tian; Zhang Yan
Journal:  Oncotarget       Date:  2017-12-06

Review 10.  Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?

Authors:  Ana Luísa Coelho; Mónica Patrícia Gomes; Raquel Jorge Catarino; Christian Rolfo; Agostinho Marques Lopes; Rui Manuel Medeiros; António Manuel Araújo
Journal:  Oncotarget       Date:  2017-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.